Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed. The data were presented at the 2011 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held June 1-4 in Montreal, Canada. AMPYRA is an oral medication approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
"People with MS often experience a progressive decline in their walking ability that can begin early in their disease course. However, in many cases patients and their healthcare providers do not discuss walking impairment until it is so severe that it requires physical support from canes or walkers," said Ron Cohen, M.D., Acorda's President and CEO. "These data show that people with MS, even those with less obvious walking impairment, can potentially experience meaningful clinical benefit from treatment with AMPYRA."
The poster presentation, entitled "Impact of Dalfampridine on MSWS-12 Score Change in MS Patients" (poster S70), examined improvements in walking ability as measured by the MSWS-12 when patients were stratified using two separate criteria: EDSS score and baseline walking speed as measured by the Timed 25-Foot Walk (T25FW). The MSWS-12 is a patient-reported questionnaire that assesses the impact of MS on various aspects of walking ability in everyday life. The presentation was based on a pooled analysis of data from one Phase 2 and two Phase 3 clinical trials of dalfampridine, which were the pivotal trials included in the New Drug Application that formed the basis of the U.S. Food and Drug Administration approval of the drug.
When stratified by baseline EDSS score (≤4.5, 5.0-5.5, ≥6.0), improvements in MSWS-12 scores among AMPYRA responders were clinically relevant and substantially greater compared to non-responders and placebo-treated patients across all three EDSS groups. Responders were defined as patients whose walking speed was faster on at least 3 of 4 on-treatment visits than their fastest speed at any of 5 off-treatment visits.
Similarly, when patients were stratified into four groups by baseline walking speed, AMPYRA responders experienced clinically relevant improvements across all four groups.
A second poster on AMPYRA data presented at the CMSC meeting, "UTI Incidence Among MS Patients Treated with Dalfampridine 10 mg Twice Daily" (poster S157), analyzed the incidence of urinary tract infection (UTI) reported by MS patients treated with AMPYRA in clinical trials, extension studies, and postmarketing safety reports. Approximately 80% of newly diagnosed MS patients and up to 96% of patients who have had MS for 10 years or more normally experience some bladder dysfunction, and UTI is a frequent complication of this dysfunction.
In the pooled Phase 2 and Phase 3 clinical trial data of 400 patients receiving AMPYRA twice daily and 238 patients receiving placebo referenced above, 14.5% of AMPYRA-treated patients reported experiencing a UTI compared to 9.2% of placebo-treated patients over treatment observations periods of 9 to 14 weeks. The incidence of serious UTIs was similar across the AMPYRA and placebo groups; there were no discontinuations in the clinical trials due to UTI as an adverse event. Neither urinalysis nor culture was required for a UTI diagnosis in the clinical trials, which was usually based on symptoms. Among 483 patients who enrolled in AMPYRA open-label extension studies, UTI was reported in 33.1% of patients, with observation periods ranging from 1-182 weeks.
New EULAR recommendations provide updated treatment strategies for systemic sclerosis